The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Quinodis     6,8-difluoro-1-(2- fluoroethyl)-7-(4...

Synonyms: Megalone, Megalocin, Fleroxicin, fleroxacin, Fleroxacino, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of fleroxacin

  • A rabbit model of CAUTI using a closed urinary catheter drainage system and the mutant strain of Escherichia coli (WE 6933) were used to examine three dosage regimens (30 mg/kg q8h i.v.; 20 mg/kg q8h i.v.; and 10 mg/kg q8h++i.v.) of fleroxacin administered intravenously for 4 days [1].
  • Fleroxacin and the three other quinolones were all active against Enterobacteriaceae, with 95-97% of the strains susceptible [2].
  • The trifluoroquinolone fleroxacin inhibits the majority of Enterobacteriaceae at concentrations < or = 1 micrograms/mL and most Pseudomonas aeruginosa and staphylococci at < or = 2 micrograms/mL [3].
  • The eradication rate for Staphylococcus aureus was 100% (11 of 11) in the fleroxacin group and 89% (17 of 19) in the AMX/CP group; 18 (82%) of the fleroxacin group and 25 (76%) of the AMX/CP group were clinically cured [4].
  • One Haemophilus parainfluenzae strain persisted with fleroxacin [5].
 

Psychiatry related information on fleroxacin

  • Clinical cure was achieved in 12 (60%) and 18 (81.8%) patients, and improvement in 2 (10%) and 1 (4.5%) patients in the fleroxacin and conventional therapy group, respectively [6].
 

High impact information on fleroxacin

 

Chemical compound and disease context of fleroxacin

 

Biological context of fleroxacin

 

Anatomical context of fleroxacin

 

Associations of fleroxacin with other chemical compounds

 

Gene context of fleroxacin

 

Analytical, diagnostic and therapeutic context of fleroxacin

References

  1. Therapeutic efficacy of fleroxacin for eliminating catheter-associated urinary tract infection in a rabbit model. Morck, D.W., Olson, M.E., McKay, S.G., Lam, K., Prosser, B., Cleeland, R., Costerton, J.W. Am. J. Med. (1993) [Pubmed]
  2. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers. Beskid, G., Prosser, B.L. Am. J. Med. (1993) [Pubmed]
  3. In vitro activity of fleroxacin in combination with other antimicrobial agents. Neu, H.C., Chin, N.X. Am. J. Med. (1993) [Pubmed]
  4. Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. Smith, J.W., Nichols, R.L. Am. J. Med. (1993) [Pubmed]
  5. Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. Chodosh, S. Am. J. Med. (1993) [Pubmed]
  6. A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. Chen, Y.W., Chen, Y.S., Lee, S.S., Yen, M.Y., Wann, S.R., Lin, H.H., Huang, W.K., Liu, Y.C. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. (2002) [Pubmed]
  7. Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin. Kletter, Y., Riklis, I., Shalit, I., Fabian, I. Blood (1991) [Pubmed]
  8. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Iravani, A. Am. J. Med. (1993) [Pubmed]
  9. Overview of the pharmacokinetics of fleroxacin. Nightingale, C.H. Am. J. Med. (1993) [Pubmed]
  10. Randomized double-blind trial of high- and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection. Pittman, W., Moon, J.O., Hamrick, L.C., Cox, C.E., Clark, J., Childs, S., Pizzuti, D., Fredericks, J., St Clair, P. Am. J. Med. (1993) [Pubmed]
  11. Multicenter trial of fleroxacin versus ceftriaxone in the treatment of uncomplicated gonorrhea. Smith, B.L., Mogabgab, W.J., Dalu, Z.A., Jones, R.B., Douglas, J.M., Handsfield, H.H., Hook, E.W., Viner, B.L., Shands, J.W., McCormack, W.M. Am. J. Med. (1993) [Pubmed]
  12. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. Tassler, H. Am. J. Med. (1993) [Pubmed]
  13. Pharmacokinetics of fleroxacin in renal impairment. Weidekamm, E. Am. J. Med. (1993) [Pubmed]
  14. Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women. Dan, M., Weidekamm, E., Sagiv, R., Portmann, R., Zakut, H. Antimicrob. Agents Chemother. (1993) [Pubmed]
  15. In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Manek, N., Andrews, J.M., Wise, R. Antimicrob. Agents Chemother. (1986) [Pubmed]
  16. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. Schrenzel, J., Cerruti, F., Herrmann, M., Leemann, T., Weidekamm, E., Portmann, R., Hirschel, B., Lew, D.P. Antimicrob. Agents Chemother. (1994) [Pubmed]
  17. Penetration of fleroxacin into body tissues and fluids. Weidekamm, E., Portmann, R. Am. J. Med. (1993) [Pubmed]
  18. Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections. Cox, C.E. Am. J. Med. (1993) [Pubmed]
  19. Comparison of fleroxacin and amoxicillin in the treatment of uncomplicated urinary tract infections in women. Whitby, M., Brown, P., Silagy, C., Rana, C. Am. J. Med. (1993) [Pubmed]
  20. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. Jynge, P., Skjetne, T., Gribbestad, I., Kleinbloesem, C.H., Hoogkamer, H.F., Antonsen, O., Krane, J., Bakøy, O.E., Furuheim, K.M., Nilsen, O.G. Clin. Pharmacol. Ther. (1990) [Pubmed]
  21. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Naber, K.G., Theuretzbacher, U., Kinzig, M., Savov, O., Sörgel, F. Antimicrob. Agents Chemother. (1998) [Pubmed]
  22. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria. Piddock, L.J., Panchal, S., Norte, V. J. Antimicrob. Chemother. (1993) [Pubmed]
  23. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes. Matera, G., Berlinghieri, M.C., Foti, F., Barreca, G.S., Focà, A. J. Antimicrob. Chemother. (1996) [Pubmed]
  24. In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone. Polak, A. Mycoses (1990) [Pubmed]
  25. Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli. Chapman, J.S., Bertasso, A., Cummings, L.M., Georgopapadakou, N.H. Antimicrob. Agents Chemother. (1995) [Pubmed]
  26. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Chin, N.X., Brittain, D.C., Neu, H.C. Antimicrob. Agents Chemother. (1986) [Pubmed]
  27. Safety of fleroxacin in clinical trials. Geddes, A.M. Am. J. Med. (1993) [Pubmed]
  28. Pharmacokinetics of fleroxacin as studied by positron emission tomography and [18F]fleroxacin. Rubin, R.H., Livni, E., Babich, J., Alpert, N.M., Liu, Y.Y., Tham, E., Prosser, B., Cleeland, R., Callahan, R.J., Correia, J.A. Am. J. Med. (1993) [Pubmed]
 
WikiGenes - Universities